AbbVie CEO Richard Gonzalez reportedly brought home $21 million in 2018, according to a FiercePharma report, with almost $4 million of that coming from a performance-based incentive award.
According to the report, Gonzalez’s compensation is heavily tied with the success of the drugmaker’s megablockbuster drug, Humira.
Sen. Ron Wyden during a Senate Finance Committee hearing last week questioned Gonzalez about his pay, asking whether a lower price for Humira would lead to a smaller bonus.
“Humira was one element to a set of financial factors that were evaluated as part of my compensation,” Gonzalez said. “It’s obviously a very significant product for us. So it’s clear that would be part of that evaluation.”
To read the full report on FiercePharma, click here.